Further details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. Project co-chairs; should be considered co-first authors.
Eur Respir J. 2015 Apr;45(4):879-905. doi: 10.1183/09031936.00009015.
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and resource use worldwide. The goal of this official American Thoracic Society (ATS)/European Respiratory Society (ERS) research statement is to describe evidence related to diagnosis, assessment and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management. Clinicians, researchers, and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarised, and then salient knowledge gaps were identified. Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus. Great strides have been made in the diagnosis, assessment and management of COPD, as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ERS research statement highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centred outcomes.
慢性阻塞性肺疾病（COPD）是全球发病率、死亡率和资源利用的主要原因。本美国胸科学会（ATS）/欧洲呼吸学会（ERS）官方研究声明的目的是描述与诊断、评估和管理相关的证据；确定知识空白；并为未来的研究提出建议。它不旨在提供 COPD 诊断和管理的临床实践建议。邀请了在 COPD 方面具有专业知识的临床医生、研究人员和患者倡导者参与。对 Medline 进行了文献检索，并选择了被认为相关的研究。该搜索不是对证据的系统评价。评估和总结了现有证据，并确定了明显的知识空白。通过讨论和共识制定了针对 COPD 所有领域中重要证据空白的研究建议，以解决这些问题。在 COPD 的诊断、评估和管理以及发病机制的理解方面已经取得了很大的进展。尽管如此，仍有许多重要的问题尚未得到解答。本 ATS/ERS 研究声明强调了领先的临床医生、研究人员和患者倡导者认为将对以患者为中心的结果产生最大影响的研究类型。
